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Abstract
Systemic sclerosis is a rare autoimmune disorder with a historically bad prognosis. 
Survival has been improving over time and we can currently estimate a 1-year survival, 
94.9; a 5-year survival, 84.4; a 10-year survival, 70.9 and a 20-year survival, 44.9%, from 
the time of diagnosis. Accordingly, mortality has been decreasing over time, being the 
overall standardized mortality ratio (SMR) 2.72 (1.90–3.83), SMR 2.4 after 1990. Among 
the SSc-related causes of death, the lung death is the most important cause and its relative 
percentage is increasing over time since the introduction of ACE inhibitors for the treat-
ment of scleroderma renal crisis (SRC) in early 1990s. Among the SSc-non-related causes 
of death, cancer, infection and cardiovascular disorders are the leading causes of death. 
Risk factor predictors of poor outcomes are an elder age at diagnosis, the male gender, 
diffuse subset, visceral involvement and non-Raynaud’s phenomenon onset.
Keywords: systemic sclerosis, survival, mortality, death, prognosis
1. Introduction
Systemic sclerosis (SSc) represents one of the autoimmune systemic diseases with worse prog-
nosis. It was actually a devastating scenario until it became well advanced in the twentieth 
century in terms of survival and mortality, but since late 1980s, the knowledge and course of 
scleroderma have been progressively improving. Nowadays, more risk factors are recognized 
and allow physicians to focus on patients with worse prognosis. As traditional SSc-related 
involvements improved, secondary involvements or SSc-non-related diseases have gained 
prominence.
© 2017 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
Attribution L cense (http://creativecommons. /licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Study Country Years (mid- 
cohort)
1-year 
survival
5-year 
survival
10-year 
survival
20-year 
survival
From onset/
diagnosis
Tuffanelli [1] The USA 1935–1958(46) NA 70.3% 69% NA Diagnosis
Farmer [2] The USA 1945–1952(48) NA 53% NA NA Diagnosis
Bennet [3] The UK 1947–1970(58) 94% 73% 50% NA Diagnosis
Medsger [4] The USA 1955–1970(62) 78% 48% NA NA Diagnosis
Zarafonetis [5] The USA 1948–1980(64) NA 81.4% 69.4% NA Diagnosis
Medsger [6] The USA 1963–1970(66) 70% 44% NA NA Diagnosis
Rowell [7] The UK 1960–1975(67) NA NA 74% NA Onset (first 
Raynaud)
Barnett [8] AUS 1953–1983(68) NA 83.6% 59.3% 27.1% Onset (first 
Raynaud)
Gouet [9] FR 1960–1984(72) 88% 62.5% 50.5% NA Diagnosis
2. Survival
Scleroderma was a devastating disease for ages. Physicians were short of proper tools to 
change significantly the prognosis of the disease since late 1980s–early 1990s due to the 
introduction of new therapies, firstly angiotensin converting enzyme (ACE) inhibitors for 
the treatment of the scleroderma renal crisis (SRC) and, in late 1990s-early 2000s, due to the 
implementation of pulmonary arterial hypertension (PAH) treatment with new drugs such 
as phosphodiesterase five (PDE5) inhibitors and antagonists of the receptor of endothelin 
(AREs). Survival has improved over time, measured at any time of the follow-up, from onset 
(in most studies described in the form of Raynaud’s phenomenon) as well as from diagnosis 
and what is more important is that it keeps improving. This is true that survival in all stages 
has improved but especially 1-year and 5-year survival. Since late death is related the most to 
SSc-non-related causes, it might be reflecting the fact that physicians are improving signifi-
cantly the prognosis of SSc-related involvements but not that much in other SSc-non-related 
diseases. Thus, just like in other autoimmune diseases, scleroderma is becoming step-by-step 
a chronic disease and not a terminal and deleterious diagnosis.
Prior to the assessment of survival of any cohort, we must pay attention to the methodology 
of the study because there is a huge variability among them, sometimes assessing survival 
from diagnosis and sometimes from the onset of disease. These last data are obviously a more 
imprecise data but certainly more real. Several survival and mortality studies from single 
cohorts and reviews have been published from the last mid-century, reporting data about 
cumulative survival at different times of follow-up and measured sometimes from the onset 
of disease and sometimes from the time of diagnosis (Table 1) [1–42].
We show data previously released in Seminars in Arthritis and Rheumatism in the last and 
more precise meta-analysis, so that we can currently predict at the time of diagnosis: a 1-year 
survival, 94.9; a 5-year survival, 84.4; a 10-year survival, 70.9 and a 20-year survival, 44.9% 
(Table 2 and Figure 1) [43].
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Study Country Years (mid- 
cohort)
1-year 
survival
5-year 
survival
10-year 
survival
20-year 
survival
From onset/
diagnosis
Giordano [10] ITA 1965–1983(74) NA 72% 32% NA Diagnosis
Altman [11] The USA 1973–1977(75) NA 63% 42% NA Diagnosis
Eason [12] NZ 1970–1980(75) 85% 60% 42% NA Diagnosis
Wynn [13] The USA 1970–1980(75) 98.4% 68.9% 51.2% 31.7% Diagnosis
Peters-Golden [14] The USA 1972–1983(77) 84% 66% 60% NA Diagnosis
Ferri [15] ITA 1955–1999(77) NA 83% 69.2% 45.5% Diagnosis
Lally [16] The USA 1972–1984(78) NA 77% NA NA Diagnosis
Jacobsen [17] DEN 1960–1996(78) NA 81% 71% 42% Onset 
(first non-
Raynaud’s 
symptom)
Kuwana [18] JAP 1971–1990(80) NA NA NA NA Diagnosis
Geirsson [19] ICE 1975–1990(82) NA 100% 81% NA Diagnosis
Kaburaki [20] JAP 1976–1991(83) NA 78% 68.2% NA Diagnosis
Nishioka [21] JAP 1974–1994(84) NA 93.7% 82% 56.7% Onset (first 
Raynaud)
Simeón [22] SPA 1976–1996(86) NA 71% 64% 62% Onset (first 
Raynaud)
Bulpitt [23] The USA 1982–1992(87) 92% 68% NA NA Onset 
(first non-
Raynaud’s 
symptom)
Bryan [24] The UK 1982–1992(87) NA 87% 75% NA Onset 
(first non-
Raynaud’s 
symptom)
Nagy [25] HUN 1982–1993(87) NA 82.9% 70.4% NA Onset 
(first non-
Raynaud’s 
symptom)
Hesselstrand [26] SWE 1983–1995(89) NA 92% 78% NA Onset 
(first non-
Raynaud’s 
symptom)
NA 86% 69% NA Diagnosis
Kim [27] KOR 1972–2007(89) NA 85.4% 80.1% NA Diagnosis
Mayes [28] The USA 1989–1991(90) NA 77.9% 55.1% 26.8% Diagnosis
Hashimoto [29] JAP 1973–2008(90) NA NA 88% 77.4% Onset (first 
Raynaud)
Pérez-Bocanegra 
[30]
SPA 1976–2007(91) NA 89% 81% 63% Diagnosis
Alamanos [31] GRE 1981–2002(91) NA 83% 70% NA Diagnosis
Survival, Mortality, Causes of Death and Risk Factors of Poor Outcome
http://dx.doi.org/10.5772/intechopen.68549
63
Study Country Years (mid- 
cohort)
1-year 
survival
5-year 
survival
10-year 
survival
20-year 
survival
From onset/
diagnosis
Nihtyanova [32] The UK 1990–1993(91) NA 84.2% NA NA Diagnosis
2000–2003(01) NA 89.9% NA NA Onset 
(first non-
Raynaud’s 
symptom)
Joven [33] SPA 1980–2006(93) 95% 85% 75% 55% Onset 
(first non-
Raynaud’s 
symptom)
Ruangjutipopan [34] THAI 1987–2001(94) NA 73% 67.4% NA Onset (no 
definition)
Czirják [35] HUN 1983–2005(94) NA 84% 72.6% NA Diagnosis
Arias-Núñez [36] SPA 1988–2006(97) NA 83.9% 64.9% NA Diagnosis
Alba [37] SPA 1986–2010(98) NA 90.7% NA NA Diagnosis
Al-Dhaher [38] CAN 1994–2004(99) NA 90% 82% NA Diagnosis
Sampaio-Barros [39] BRA 1991–2010(00) NA 90% 84% NA Onset (no 
definition)
Hoffmann-Vold [40] NOR 1999–2009(04) NA 95% 86% NA Onset 
(first non-
Raynaud’s 
symptom)
Vettori [41] ITA 2000–2008(04) NA 94.8 NA NA Onset (first 
Raynaud)
Kuo [42] TAIW 2002–2007(05) 94.9% 83.2% NA NA Diagnosis
NA: non-available. Reprinted from Rubio-Rivas et al. [43], with permission from Elsevier.
Table 1. Survival studies on scleroderma [43].
Survival from onset (first  
Raynaud)
Survival from onset (first non-
Raynaud’s symptom)
Survival from diagnosis
Before 1990  
(five studies)
After 1990 
(three 
studies)
p Before 1990 
(four studies)
After 1990 
(three 
studies)
p Before 
1990 (18 
studies)
After 1990 
(eight 
studies)
p
Number of 
patients
840 1693 846 802 4365 3476
1-year survival% 
mean (SD)
– – – 92 (NA) 95 (NA) – 85.3(9.5) 94.9(NA) 0.384
5-year survival% 
mean (SD)
85.1(10.4) 92.8(2.9) 0.385 79.7 (8.2) 90 (5.0) 0.118 70.6(14.3) 84.4(3.8) 0.001
10-year 
survival% mean 
(SD)
71.5(9.5) 88(NA) 0.189 72.1 (2.5) 80.5 (7.8) 0.358 58.8(14.8) 70.9(10.1) 0.086
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Survival from onset (first  
Raynaud)
Survival from onset (first non-
Raynaud’s symptom)
Survival from diagnosis
Before 1990  
(five studies)
After 1990 
(three 
studies)
p Before 1990 
(four studies)
After 1990 
(three 
studies)
p Before 
1990 (18 
studies)
After 1990 
(eight 
studies)
p
20-year 
survival% mean 
(SD)
48.6(18.8) 77.4(NA) 0.316 42 (NA) 55 (NA) – 38.6(9.8) 44.9(25.6) 0.790
T-test for independent groups among studies before and after 1990 (mid-cohort year). NA: non-available. Reprinted 
from Rubio-Rivas et al. [43], with permission from Elsevier.
Table 2. Survival studies on scleroderma [43].
Figure 1. Survival evolution over time. Meta-regression. Five-year survival (coefficient b = 0.308 and p = 0.402) and 10-year 
survival (coefficient b = 0.595 and p = 0.237) from the onset (first Raynaud). Five-year survival (coefficient b = 0.612 and 
p = 0.113) and 10-year survival (coefficient b = 0.590 and p = 0.037) from the onset (first non-Raynaud’s symptom). Five-
year survival (coefficient b = 0.595 and p < 0.001) and 10-year survival (coefficient b = 0.536 and p = 0.025) from diagnosis. 
Reprinted from Rubio-Rivas et al., with permission from Elsevier [43].
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3. Mortality
SSc is an autoimmune disease with a broad spectrum of severity, ranging from a mild disease to 
a devastating one. The most valuable parameter in order to compare mortality (instead of a crude 
mortality rate) is the assessment of the SMR, a fundamental tool in the only five mortality meta-
analyses reported so far in SSc (Table 3). The SMR is the ratio between observed mortality and 
expected mortality in sex- and age-matched general population. These five meta-analyses are 
based on the assessment of the SMR: Elhai et al. {nine studies, overall SMR is 3.53 (3.03–4.11)} [45], 
Loannidis et al. {seven studies} [44], Toledano et al. {seven studies, overall SMR 3.51 (2.74–4.50)} 
[46], Komócsi et al. {10 studies, overall SMR 3.24} [47] and Rubio-Rivas et al. {17 studies, overall 
SMR 2.72 (1.90–3.83)} [43]. In base of this last study based on 17 studies, we could state that mor-
tality is over 2.7-fold compared to the general population (Table 4 and Figure 2) [5, 17, 24, 26, 29, 
30, 31, 33, 37, 40, 42, 48–53]. Mortality has been decreasing over time and notoriously after 1990, 
being more reasonable to accept nowadays an SMR over 2.4-fold in a patient diagnosed today 
(Figure 2). Obviously, prognosis should be individualized since different risk factors present at 
diagnosis or during the follow-up can modify this predicted SMR. For instance, SMR in males 
and dcSSc subset is expected to be worse compared to SMR in females or lcSSc subset (Figure 3).
Study Year of publication Number of studies included SMR (95% CI)
Ioannidis et al. [44] 2005 7 –
Elhai et al. [45] 2012 9 3.53 (3.03–4.11)
Toledano et al. [46] 2012 7 3.51 (2.74–4.50)
Komócsi et al. [47] 2012 10 3.24 (NA)
Rubio-Rivas et al. [43] 2014 17 2.72 (1.93–3.83)
NA: non-available.
Table 3. Meta-analyses on scleroderma and mortality.
Study Country Years (mid-
cohort year)
Death Overall SMR 
(95%CI)
dcSSc SMR 
(95%CI)
lcSSc SMR 
(95%CI)
Male SMR 
(95%CI)
Female SMR 
(95%CI)
Zarafonetis [5] US 1948–1980 
(64)
142 5.40 
(3.17-7.63)
NA NA NA NA
Jacobsen [17] DEN 1960–1996 
(78)
160 2.90 
(2.50-3.40)
4.50 
(3.50-5.70)
2.30 
(1.80-2.80)
3.70 
(2.70-5.10)
2.70 
(2.30-3.30)
Abu-Shakra 
[48]
CAN 1976–1990 
(83)
61 4.69 
(3.73-5.65)
6.18 
(4.17-8.81)
3.80 
(2.58-5.39)
4.18 
(2.09-7.48)
4.81 
(3.65-6.44)
Walsh [49] US 1981–1990 
(85)
2123 1.05 
(1.01-1.1)
NA NA NA NA
Bryan [24] UK 1982–1992 
(87)
55 4.05 
(3.03-5.22)
NA NA 3.22 
(1.85-4.97)
4.59 
(3.22-6.19)
Hesselstrand 
[26]
SWE 1983–1995 
(89)
49 4.59 
(3.48-6.07)
6.06 
(4.09-9.02)
3.72 
(2.41-532)
4.77 
(3.21-7.09)
4.44 
(2.87-6.34)
Hashimoto 
[29]
JAP 1973–1908 
(90)
86 2.76 
(2.18-3.35)
5.90 
(4.20-7.61)
1.71 
(1.18-2.24)
3.31 
(1.15-5.47)
2.71 
(2.10-3.32)
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Study Country Years (mid-
cohort year)
Death Overall SMR 
(95%CI)
dcSSc SMR 
(95%CI)
lcSSc SMR 
(95%CI)
Male SMR 
(95%CI)
Female SMR 
(95%CI)
Alamanos [31] GRE 1981–2002 
(91)
36 2.0 (1.2-2.8) NA NA NA NA
Scussel-
Lonzetti [50]
CAN 1984–1999 
(91)
66 2.69 
(2.10-3.40)
6.17 
(2.80-11.70)
2.71 
(1.85-3.80)
1.76 
(0.80-3.30)
2.55 
(1.90-3.30)
Pérez-
Bocanegra [30]
SPA 1976–2007 
(91)
73 1.90 
(1.50-2.30)
6.50 
(4.10-9.80)
1.70 
(1.20-2.20)
1.80 
(0.80-3.40)
2.50 
(1.90-3.20)
Joven [33] SPA 1980–2006 
(93)
44 3.10 
(1.60-6.10)
NA NA NA NA
Alba [37] SPA 1986–2010 
(98)
151 3.80 
(3.18-4.43)
NA NA NA NA
Hissaria [51] AUS 1993–2007 
(00)
331 1.46 
(1.28-1.69)
2.92 
(2.20-3.89)
1.30 
(1.11-1.53)
NA NA
Mok [52] CHI 1999–2008 
(03)
110 3.94 
(3.20-4.68)
NA NA 2.59 
(1.32-3.87)
4.32 
(3.45-5.20)
Hoffmann-
Vold [40]
NOR 1999–2009 
(04)
43 2.03 
(1.40-2.60)
5.33 
(3.90-10.30)
1.62 
(1.10-2.50)
2.61 
(1.40-3.90)
1.80 
(1.20-2.70)
Strickland [53] UK 1999–2010 
(04)
53 1.34 
(0.95-1.74)
1.66 
(0.83-2.97)
1.27 
(0.92-1.72)
1.54 
(0.67-3.04)
1.30 
(0.95-1.74)
Kuo [42] TAIW 2002–2007 
(05)
204 3.24 
(2.82-3.71)
NA NA 3.53 
(2.97-4.16)
2.92 
(2.29-3.66)
NA: non-available, SMR: standardized mortality ratio, dcSSc: diffuse cutaneous systemic sclerosis and lcSSc: limited 
cutaneous systemic sclerosis. Reprinted from Rubio-Rivas et al. [43], with permission from Elsevier.
Table 4. Studies included in the SMR meta-analysis by Rubio-Rivas et al [43].
Figure 2. SMR meta-analysis. The overall SMR (discontinuous points) is 2.71 (1.95–3.75). SMR before 1990 (continuous 
line) is 3.33 (1.64–6.75). SMR after 1990 (discontinuous lines) is 2.42 (1.89–3.11). Forest plot. Meta-regression of change 
in SMR (lnSMR) with mid-cohort year (Coefficient b = –0.055 and p = 0.064). Reprinted from Rubio-Rivas et al., with 
permission from Elsevier [43].
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4. Causes of death
As in other autoimmune diseases, the pattern of mortality has been changing over time since 
the autoimmune disease by itself has been the main cause of death in these patients for ages 
but the more physicians control the disease, the more likely it is to die due to other causes not 
directly related to SSc [43, 54–56].
4.1. SSc-related causes of death
Among the SSc-related causes, there are four major organs potentially involved: the lungs, 
heart, kidneys and gastrointestinal tract. Among them, lung and renal involvement were the 
most important as a cause of death during the twentieth century (Table 5) [2, 3, 7, 8, 11–13, 15, 
17–19, 21–24, 26, 29, 31, 33–42, 48, 50–53, 56, 57, 59–62].
Figure 3. SMR meta-analysis. For the male gender, overall SMR is 3.18 (2.62–3.85) and for the female gender, overall 
SMR is 2.81 (2.25–3.50); for dcSSc subtype, the overall SMR is 4.73 (3.69–6.07) and for lcSSc subtype, overall SMR is 2.04 
(1.55–2.68). Forest plot. Reprinted from Rubio-Rivas et al., with permission from Elsevier [43].
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4.1.1. Lung involvement
In the case of lung involvement, death can be due to the progression towards respiratory fail-
ure due to PAH or interstitial lung disease (ILD).
In the case of PAH, evidence suggests that SSc-PAH patients have a worse response to ther-
apy when compared to idiopathic PAH. New therapies (phosphodiesterase type 5 inhibi-
tors and endothelin receptor antagonists) have improved its prognosis but not that much 
and thus, this is still a severe manifestation of the disease and a frequent cause of death. An 
early combination schedule of treatment has been suggested to be better in terms of prog-
nosis. However, more studies are required to demonstrate and standardize this strategy of 
treatment [63].
Interstitial lung disease constitutes the most severe manifestation of the disease and is in fact 
the first cause of death in these patients (Figure 4). Therefore, it is crucial to perform a regu-
lar screening of this involvement and an early treatment when diagnosed. Patients showing 
the following criteria would warrant an immunosuppressive treatment: (1) either an extent 
of lung disease >20% on High-resolution computed tomography (HRCT) or an indetermi-
nate extent (disease extent not readily classifiable as minimal or severe; HRCT extent is 
10–30%) of disease plus an FVC < 70%, (2) patients experiencing a significant decrease in 
pulmonary functional assessment during the follow-up (FVC > 10% or DLco >15% or both, 
whatever the extent of lung involvement is for 12 months). Currently, the management 
of SSc–ILD is largely confined to immunomodulvation. Non-selective immunosuppres-
sants such as cyclophosphamide followed by mycophenolate mofetil and azathioprine are 
still the most widely used medications in SSc-ILD. Several alternative approaches may be 
considered, including B cell depletion therapies (rituximab), anti-TGF-β antibody, tyrosine 
kinase inhibitors (imatinib, dasatinib), anti-IL-6 antibody, anti-IL-13 antibody, pirfenidone 
and haematopoietic stem cell transplantation (HSCT). Finally, lung transplantation may 
be limited to those patients, with severe SSc-ILD, unresponsive to pharmacologic therapy  
[64]. It is important to remember that, although often used, during the first stages of treat-
ment, prednisone doses over 15 mg a day can be dangerous in order to trigger a sclero-
derma renal crisis.
4.1.2. Renal involvement
Scleroderma renal crisis occurs during the rapid progression of skin thickening in the early 
stages of dcSSc (<5 years after disease onset). Several case series published during the past 20 
years and a 2013 systematic literature review has estimated that SRC develops in 5–15 and 
15% of patients with dcSSc, respectively. Interestingly, the incidence and prevalence of SRC 
seem to be decreasing over time, possibly as a result of early recognition and management 
of SRC risk factors and early signs and symptoms in patients with dcSSc [65]. The introduc-
tion of ACE inhibitors (captopril) reduced dramatically its frequency as the cause of death 
since early 1990s of the past century (Figure 4). Besides, its incidence is decreasing but due 
to unknown reasons. The extended use of ACE inhibitors prescribed for other reasons (i.e. 
arterial hypertension or heart failure) has not been found as the cause of this decreasing 
incidence.
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Country Years (mid-
cohort year)
Deads/n SSc-related 
death
Lung  
death
Heart 
death
Kidney 
death
GI death
Farmer [2] US 1945–1952 
(48)
115/271 
(49%)
17 (14.8%) 5 (29.4%) 6 
(35.3%)
1 (5.9%) 1 (5.9%)
Bennet [3] UK 1947–1970 
(58)
26/67 
(38.8%)
1 (9.1%) 0 (0%) 1 (9.1%) 0 (0%) 0 (0%)
Rowell [7] UK 1960–1975 
(67)
22/84 
(26.2%)
NA NA NA NA NA
Barnett [8] AUS 1953–1983 
(68)
86/177 
(48.6%)
42 (48.8%) 8 (19%) 10 
(11.6%)
16 (38.1%) 8 (9.3%)
Altman [11] US 1973–1977 
(75)
131/264 
(49.6%)
89 (68%) 19 
(21.3%)
19 
(21.3%)
35 (39.3%) 13 (14.6%)
Eason [12] NZ 1970–1980 
(75)
24/47 
(51%)
18 (75%) 7 (38.9%) 4 
(22.2%)
5 (27.8%) 2 (11.1%)
Wynn [13] US 1970–1980 
(75)
25/64 
(39.1%)
17 (68%) 7 (41.2%) 6 
(35.3%)
4 (23.5%) 0 (0%)
Ferri [15] ITA 1955–1999 
(77)
279/1012 
(27.6%)
61 (35.9%) NA NA NA NA
Lally [16] US 1972–1984 
(78)
17/91 
(18.7%)
14 (82.4%) 0 (0%) 8 
(57.1%)
6 (42.9%) 0 (0%)
Jacobsen [17] DEN 1960–1996 
(78)
160/344 
(46.5%)
41 (25.6%) 13 
(31.7%)
1 (2.4%) 17 (41.5%) 9 (22%)
Kuwana [18] JAP 1971–1990 
(80)
51/275 
(18.5%)
32 (62.7%) 23 
(71.9%)
4 
(12.5%)
5 (15.6%) 0 (0%)
Geirsson [19] ICE 1975–1990 
(82)
5/23 
(21.7%)
2 (40%) 0 (0%) 1 (50%) 1 (50%) 0 (0%)
Abu-Shakra [48] CAN 1976–1990 
(83)
61/237 
(25.7%)
44 (77.1%) 13 
(29.5%)
5 
(11.4%)
5 (11.4%) 0 (0%)
Nishioka [21] JAP 1974–1994 
(84)
90/496 
(18.1%)
64 (71.1%) 44 
(68.8%)
31 
(48.4%)
12 (18.8%) 13 (20.3%)
Steen [56] US 1972–1996 
(84)
364/1508 
(24.1%)
182 (50%) NA NA NA NA
Simeón [22] SPA 1976–1996 
(86)
12/79 
(15.2%)
11 (91.7%) 4 (36.4%) 0 (0%) 7 (63.6%) 0 (0%)
Bulpitt [23] US 1982–1992 
(87)
15/48 
(31.3%)
9 (60%) 4 (44.4%) 1 
(11.1%)
4 (44.4%) 0 (0%)
Bryan [24] UK 1982–1992 
(87)
55/283 
(19.4%)
34 (61.8%) 15 
(44.1%)
5 
(14.7%)
5 (14.7%) 3 (8.8%)
Geirsson [57] SWE 1982–1995 
(88)
30/100 
(30%)
10 (33.3%) 5 (50%) 4 (40%) 1 (10%) 0 (0%)
Hesselstrand [26] SWE 1983–1995 
(89)
49/249 
(19.7%)
15 (30.6%) 10 
(66.7%)
1 (6.7%) 1 (6.7%) 3 (20%)
Bond [58] AUS 1983–1996 
(89)
123/123 
(100%)
43 (35%) 13 
(30.2%)
14 
(32.6%)
6 (14%) NA
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Country Years (mid-
cohort year)
Deads/n SSc-related 
death
Lung  
death
Heart 
death
Kidney 
death
GI death
Vlachoyiannopoulos 
[59]
GRE 1982–1996 
(89)
7/254 
(2.8%)
6 (85.7%) 2 (33.3%) 2 
(33.3%)
2 (33.3%) 0 (0%)
Hashimoto [29] JAP 1973–1908 
(90)
86/405 
(21.2%)
NA NA NA NA NA
Scussel-Lonzetti [50] CAN 1984–1999 
(91)
66/309 
(21.4%)
35 (53%) 6 (17.1%) 4 
(11.4%)
7 (20%) 3 (8.6%)
Alamanos [31] GRE 1981–2002 
(91)
36/109 
(33%)
23 (63.9%) 21 
(58.3%)
21 
(58.3%)
2 (5.6%) 0 (0%)
Joven [33] SPA 1980–1906 
(93)
44/204 
(21.6%)
36 (82%) 20 
(55.6%)
8 
(22.2%)
1 (2.8%) 3 (8.3%)
Ruangjutipopan [34] THAI 1987–2001 
(94)
31/222 
(26.7%)
18 (58.1%) NA NA NA 0 (0%)
Czirják [35] HUN 1983–-2005 
(94)
93/366 
(25.4%)
86 (92.5%) 30 
(34.9%)
29 
(33.7%)
16 (18.6%) 8 (9.3%)
Derk [60] US 1985–2007 
(96)
87/87 
(100%)
67 (77%) 65 (97%) 55 
(82.1%)
2 (3%) 0 (0%)
Arias-Núñez [36] SPA 1988–2006 
(97)
20/78 
(25.6%)
11 (55%) 10 
(90.9%)
1 (9.1%) 0 (0%) 0 (0%)
Alba [37] SPA 1986–2010 
(98)
151/1037 
(14.6%)
61 (78.2%) NA 13 
(16.7%)
0 (0%) 5 (4.1%)
Al-Dhaher [38] CAN 1994–2004 
(99)
42/185 
(23%)
NA 15 
(45.5%)
9 
(27.3%)
9 (27.3%) 0 (0%)
Sampaio-Barros [39] BRA 1991–2010 
(00)
168/947 
(17.7%)
110 (65.5%) 53 
(48.2%)
27 
(24.5%)
12 (10.9%) 5 (4.5%)
Assassi [61] US 1998–2008 
(03)
52/250 
(20.8%)
29 (55.8%) 10 
(34.5%)
4 
(13.8%)
NA 2 (6.9%)
Mok [52] CHI 1999–2008 
(03)
110/449 
(24.5%)
26 (24%) 11 
(42.3%)
NA 5 (19.2%) 2 (7.7%)
Hoffmann-Vold [40] NOR 1999–2009 
(04)
43/312 
(13.8%)
13 (54.2%) 0 (0%) 5 
(20.8%)
6 (25%) 2 (4.7%)
Vettori [41] ITA 2000–2008 
(04)
20/251 
(8%)
12 (60%) 5 (41.7%) 4 
(33.3%)
1 (8.3%) 2 (16.7%)
Hachulla [62] FR 2002–2006 
(04)
47/546 
(8.6%)
24 (51.1%) 19 
(79.2%)
0 (0%) 3 (12.5%) 2 (8.3%)
Strickland [53] UK 1999–2010 
(04)
53/204 
(26%)
19 (35.9%) 9 (47.4%) 4 
(21.1%)
0 (0%) 1 (5.3%)
Kuo [42] TAIW 2002–2007 
(05)
204/1479 
(13.8%)
57 (27.9%) 9 (4.4%) 29 
(0.1%)
14 (6.9%) 10 (5%)
Lung, heart, kidney and GI are deaths related to SSc. NA: non-available; GI: gastrointestinal. Reprinted from Rubio-
Rivas et al. [43], with permission from Elsevier.
Table 5. SSc-related causes of death in medical literature [43].
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Figure 4. Meta-regression of deaths due to lung over time (coefficient b = 0.935 and p = 0.005) and renal (coefficient 
b=−0.206 and p = 0.352). Reprinted from Rubio-Rivas et al., with permission from Elsevier [43].
4.1.3. Heart involvement
Despite the fact that definite SSc for cardiac involvement does not exist, we could categorize its 
involvement in five major groups: pericarditis with or without cardiac tamponade, ischemic 
cardiopathy (documented myocardial infarction, angina, ischemic alterations in myocardial 
perfusion SPECT or requirement of coronary revascularization, surgical or percutaneous), 
pacemaker bearing regardless of the time of arrhythmia, sudden death and congestive heart 
failure [66]. As it is more recognized nowadays, its ratio is increasing, but the real challenge 
in the years to come shall be to distinguish the real scleroderma involvement from a cardiac 
SSc-non-related involvement. Anyway, we can hypothesize today that this is related to SSc in 
younger patients without classical cardiovascular risk factors.
4.1.4. Gastrointestinal involvement
The gastrointestinal tract is the most affected organ after the skin and can be affected from 
the oral cavity to the anus. About 90% of all patients will be affected during follow-up. This 
involvement can result in a decreased quality of life more often than a direct cause of death. 
In fact, it has been a rare cause of death over time. The few fatal cases have been related to 
those with severe intestinal involvement leading to malabsorption and secondary starvation. 
We cannot forget the possible role of the oesophageal involvement in the development of 
interstitial lung disease [67].
4.2. SSc-non-related causes of death
Among SSc-non-related causes of death, we can find three major diseases: cancer, infections 
and cardiovascular diseases (Table 6) [2, 3, 7, 8, 11–13, 15, 17–19, 21–24, 26, 29, 31, 33–42, 48, 
50–53, 56, 57, 59–62].
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Country Years (mid- 
cohort)
Deads/n Cancer death Infection  
death
Atherosclerosis  
death
Farmer [2] US 1945–1952 (48) 115/271 (49%) 6 (5.2%) 4 (3.5%) 20 (17.4%)
Bennet [3] UK 1947–1970 (58) 26/67 (38.8%) 2 (18.2%) 3 (27.3%) 5 (45.5%)
Rowell [7] UK 1960–1975 (67) 22/84 (26.2%) 0 (0%) NA 1 (4.5%)
Barnett [8] AUS 1953–1983 (68) 86/177 (48.6%) NA NA NA
Altman [11] US 1973–1977 (75) 131/264 (49.6%) 9 (6.9%) 3 (2.3%) 17 (13%)
Eason [12] NZ 1970–1980 (75) 24/47 (51%) 2 (8.3%) 2 (8.3%) 2 (8.3%)
Wynn [13] US 1970–1980 (75) 25/64 (39.1%) 3 (12%) 0 (0%) 3 (12%)
Ferri [15] ITA 1955–1999 (77) 279/1012 (27.6%) 25 (14.7%) NA
Lally [16] US 1972–1984 (78) 17/91 (18.7%) 1 (5.9%) 2 (11.8%) 0 (0%)
Jacobsen [17] DEN 1960–1996 (78) 160/344 (46.5%) 30 (18.8%) 19 (11.9 %) 43/160
Kuwana [18] JAP 1971–1990 (80) 51/275 (18.5%) 5 (9.8%) 1 (2%) 5 (9.8%)
Geirsson [19] ICE 1975–1990 (82) 5/23 (21.7%) 1 (20%) 0 (0%) 2 (40%)
Abu-Shakra [48] CAN 1976–1990 (83) 61/237 (25.7%) 6 (9.8%) 0 (0%) NA
Nishioka [21] JAP 1974–1994 (84) 90/496 (18.1%) 21 (23.3%) 5 (5.6%) NA
Steen [56] US 1972–1996 (84) 364/1508 (24.1%) 63 (17.3%) 32 (8.8%) 30 (8.2%)
Simeón [22] SPA 1976–1996 (86) 12/79 (15.2%) 1 (8.3%) 0 (0%) 0 (0%)
Bulpitt [23] US 1982–1992 (87) 15/48 (31.3%) 1 (6.7%) 1 (6.7%) 0 (0%)
Bryan [24] UK 1982–1992 (87) 55/283 (19.4%) 1 (1.8%) 4 (7.3%) 11 (20%)
Geirsson [57] SWE 1982–1995 (88) 30/100 (30%) 9 (30%) 6 (20%) 3 (10%)
Hesselstrand [26] SWE 1983–1995 (89) 49/249 (19.7%) 12 (24.5%) 9 (18.4%) 9 (18.4%)
Bond [58] AUS 1983–1996 (89) 123/123 (100%) 10 (8.1%) 6 (4.9%) 17 (13.8%)
Vlachoyiannopoulos 
[59]
GRE 1982–1996 (89) 7/254 (2.8%) 0 (0%) 0 (0%) 0 (0%)
Hashimoto [29] JAP 1973–2008 (90) 86/405 (21.2%) 19 (22.1%) 14 (16.3%) NA
Scussel-Lonzetti [50] CAN 1984–1999 (91) 66/309 (21.4%) 13 (19.7%) NA 10 (15.2%)
Alamanos [31] GRE 1981–2002 (91) 36/109 (33%) 4 (11.1%) 1 (0.2%) 6 (16.7%)
Joven [33] SPA 1980–2006 (93) 44/204 (21.6%) 3 (6.8%) 2 (4.5%) 5 (11.4%)
Ruangjutipopan [34] THAI 1987–2001 (94) 31/222 (26.7%) 0 (0%) 13 (42%) 0 (0%)
Czirják [35] HUN 1983–2005 (94) 93/366 (25.4%) 12 (12.9%) 2 (2.2%) NA
Derk [60] US 1985–2007 (96) 87/87 (100%) 3 (4.5%) 4.6% 0 (0%)
Arias-Núñez [36] SPA 1988–2006 (97) 20/78 (25.6%) 1 (5%) 3 (15%) 2 (10%)
Alba [37] SPA 1986–2010 (98) 151/1037 (14.6%) 61 (78.2%) 18 (14.8%) NA
Al-Dhaher [38] CAN 1994–2004 (99) 42/185 (23%) NA NA NA
Sampaio-Barros [39] BRA 1991–2010 (00) 168/947 (17.7%) 8 (4.8%) 24 (14.3%) 8 (4.8%)
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Country Years (mid- 
cohort)
Deads/n Cancer death Infection  
death
Atherosclerosis  
death
Assassi [61] US 1998–2008 (03) 52/250 (20.8%) NA NA NA
Mok [52] CHI 1999–2008 (03) 110/449 (24.5%) 11 (10%) 19 (17.3%) NA
Hoffmann-Vold [40] NOR 1999–2009 (04) 43/312 (13.8%) 13 (54.2%) 6 (14%) 4 (9.3%)
Vettori [41] ITA 2000–2008 (04) 20/251 (8%) 2 (10%) 1 (5%) 2 (10%)
Hachulla [63] FR 2002–2006 (04) 47/546 (8.6%) 8 (17%) 4 (8.5%) 2 (4.3%)
Strickland [53] UK 1999–2010 (04) 53/204 (26%) 10 (18.9%) 13(24.5%) 12 (22.6%)
Kuo [42] TAIW 2002–2007 (05) 204/1479 (13.8%) 30 (14.7%) 12 (5.9%) 29 (14.2%)
Reprinted from Rubio-Rivas et al. [43], with permission from Elsevier.
Table 6. SSc-non-related causes of death in medical literature [43].
4.2.1. Cancer
A higher standardized incidence ratio (SIR) of cancer in these patients not only compared 
to the general population that could be related to immunosuppressive treatment but also to 
the self-nature of the disease has been described [68]. In fact, those cancers diagnosed within 
the first 3 years after the diagnosis of scleroderma have been suggested to be classified as 
SSc-related causes. Cancer among SSc patients with RNA polymerase III antibodies has been 
reported to be in a close temporal relationship to the onset of SSc (first 36 months after the 
onset of SSc), which supports the paraneoplastic phenomenon in this subset of patients [69]. 
Thus, it is recommended to rule out this possibility at the time of the diagnosis, although 
protocol for this purpose has not been standardized so far. Cancers most frequently found in 
SSc patients are those from breast, blood, lung, gastrointestinal tract, genitourinary tract and 
skin and, out of these, those most related to the presence of RNAp III antibodies were breast 
cancer, skin cancer and genitourinary cancer [69].
4.2.2. Infections
Risk factors associated with infections in patients diagnosed with scleroderma include 
oesophageal (increased risk for aspiration pneumonia) and interstitial lung disease (increased 
risk for pneumonia), severe Raynaud’s phenomenon or calcinosis (risk for localized super-
infections) and the use of specific treatments for the management of the disease. Bacterial 
infections due to Gram-positive bacilli have been described, especially in patients with severe 
Raynaud or calcinosis. In patients receiving immunosuppressive treatment, especially corti-
costeroids, Nocardia sp. and Mycobacteria sp. must be taken into account. A few viruses such 
as Epstein-Barr virus and CMV have been described as triggering the onset of scleroderma, 
and Parvovirus B19 DNA has been detected in patients who have scleroderma, but the clini-
cal correlate of this finding is unclear. Finally, among fungi, Pneumocystis jirovecii pneumo-
nia has been reported in some patients who have scleroderma [70]. Aspergillus sp. has been 
rarely reported in scleroderma, but in any patient under cellular immunosuppression has to 
be taken into account as well [71].
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4.2.3. Cardiovascular disease
Scleroderma, as other autoimmune diseases, shows up as an inflammatory background that 
leads to the fibroblast activation. This background is more visual in the first stages of the 
skin or lung involvement, but it is thought to happen elsewhere. Thus, scleroderma itself 
can be understood as a new cardiovascular risk factor not only involved in the develop-
ment of microvascular disease but also of macrovascular disease [72]. Atherosclerosis has 
been found to be increased in patients with SSc in all territories: coronary arteries, carotid 
arteries, cerebrovascular vessels and peripheral arteries [72]. This is the most controversial 
group of diseases in terms of classification since it is a challenge to differentiate whether it is 
an SSc-related or a SSc-non-related event. Although sometimes undistinguishable, currently, 
the clinical context has been hypothesized to aid for this purpose. Thus, in young patients 
without other classical cardiovascular risk factors (smoking behaviour, diabetes mellitus, 
arterial hypertension, hyperlipidaemia, obesity), we state that a particular event should be 
classified as SSc-related.
According to the latest studies [43], the big picture when talking about causes of death should 
be that SSc-related death is estimated nowadays in 56.7% of all deaths. Among them, repre-
senting lung death 57%, heart death 28.2%, renal death 11.7% and gastrointestinal death 6.4% 
(Table 7). In contrast, SSc-non-related death is estimated in 43.3% of all patients and among 
them being cancer, infections and cardiovascular disease the leading cause of SSc-non-related 
death.
4.3. A temporary pattern of SSc-related causes of death
In general, we could state that early death within the first years after the diagnosis of sclero-
derma is primarily due to the autoimmune disease itself, and late death is due to SSc-non 
directly related causes. Besides, this progression is currently even more notorious since data 
from the Spanish Registry show the fact that beyond 10 years after diagnosis, 83% of all deaths 
are due to SSc-non-related causes, supporting the idea that by struggling with the disease in 
the first years could save quite a few deaths due to the self-disease [54, 55].
Before 1990 (22 studies) After 1990 (18 studies) p
SSc-related deaths % mean 
(SD)
52.5 (24.7) 56.7 (17.4) 0.544
Lung 34.5 (21.3) 57.0 (24.7) 0.008
Heart 29.3 (23.8) 28.2 (28.1) 0.905
Kidney 26.4 (17.6) 11.7 (7.9) 0.003
GI 6.8 (8.7) 6.4 (7.0) 0.881
T-test for independent groups among studies before and after 1990 (mid-cohort year). GI: gastrointestinal. Reprinted 
from Rubio-Rivas et al. [43], with permission from Elsevier.
Table 7. SSc-related causes of death [43].
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Among these SSc-related causes, pulmonary death (due to ILD or PAH) has been and still 
currently is the leading SSc-related cause of death in all stages of the disease. In contrast, 
renal death was the second cause of the death in the past and most of all in the dcSSc subset 
and within the first 5 years after SSc diagnosis, but, in the last years, we have been witnesses 
of an important decrease of renal death rate. Heart death is at first sight more present nowa-
days and within the early stages of the disease but possibly due to a better understanding 
and knowledge of this involvement. Gastrointestinal death has been the cause of death only 
inisolated cases over time (Table 8).
Thus, it is expected to see an increasing rate of SSc-non-related causes in the years to come, 
mainly cancer and cardiovascular causes. Among the SSc-related causes, cardiovascular 
causes will be the cornerstone and the challenge will be to distinguish SSc-related and SSc-
non-related cardiovascular events.
5. Risk factors of poor outcome
To date, several risk factors have been identified related to poor prognosis, sometimes reported 
as a result of univariate analysis and sometimes as a result of multivariate analysis [43].
Cause of death 1990–1999 2000–2009 p
Early SSc-non-related 3 (17.6%) 23 (48.9%) 0.042
Pulmonary 8 (47.1%) 16 (34.0%) 0.390
Renal 6 (35.3%) 1 (2.1%) < 0.001
Cardiac 0 (0.0%) 7 (14.9%) 0.175
Gastrointestinal 0 (0.0%) 0 (0.0%) –
Intermediate SSc-non-related 5 (23.8%) 11 (50.0%) 0.116
Pulmonary 13 (61.9%) 6 (27.3%) 0.033
Renal 1 (4.8%) 1 (4.5%) 1.000
Cardiac 2 (9.5%) 4 (18.2%) 0.664
Gastrointestinal 0 (0.0%) 0 (0.0%) –
Late SSc-non-related 10 (37.0%) 5 (83.3%) 0.070
Pulmonary 11 (40.7%) 1 (16.7%) 0.379
Renal 1 (3.7%) 0 (0.0%) 1.000
Cardiac 4 (14.8%) 0 (0.0%) 1.000
Gastrointestinal 1 (3.7%) 0 (0.0%) 1.000
Early (first 5 years after diagnosis), intermediate (5–10 years after diagnosis) and late death ( >10 years after diagnosis) 
from the Spanish Scleroderma Network. Reprinted from Rubio-Rivas [54].
Table 8. SSc-non-related and SSc-related (lung, heart, renal and gastrointestinal) causes of death. In bold, p-values 
reaching statistical significance or close to significance.
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Taking into account the number of citations from the different studies (Figure 5), more cited 
risk factors would be an older age at diagnosis, dcSSc subset, male gender and visceral 
involvement (most of all lung, heart and renal involvement).
It is not easy to quantify the overall risk attributed to any of these factors since they have been 
described in different ways, but by meta-analysing those described homogeneously (Figure 6), 
we could state a hazard ratio for kidney involvement 4.22 (3.42–5.19), for heart involvement 
3.43 (1.35–8.70), for ILD 2.89 (2.24–3.72), for high eritrosedimentation rate 2.77 (2.06–3.71), for 
PAH 2.62 (1.64–4.17), for dcSSc 2.28 (1.69–3.08), for male gender 1.88 (1.48–2.38) and age/year 
1.05 (1.04–1.06) [43].
New risk factors are required in order to identify those patients with worse prognosis who 
could get some benefits in terms of a more aggressive therapy and/or closer follow-up. 
Recently, the mode of onset has been evaluated as a potential risk factor, finding a worse 
prognosis in those patients with an onset in the form of non-Raynaud’s phenomenon, with 
the only exception of arthralgia (data not yet released).
Anyway, the risk should be individualized and accordingly lead to the decision-making for 
every patient. Thus, it should be our aim to create prognosis scales based on these known risk 
factors.
Figure 5. Risk factors for poor outcomes (number of citations in the different studies). Into “others” are included 
proteinuria, gastrointestinal and osteoarticular involvement, high BUN, hypo/hyperpigmentation, digital ulcers, HLADQA1 
and HLA DRB1, low body mass index, hands deformity, low STC and low total lung compliance, myositis, anti-RNP 
+, S3 heart gallop, corticosteroid treatment, longer time from first Raynaud, no CREST, tobacco and alcohol uptake and 
hypoproteinaemia. Reprinted from Rubio-Rivas et al., with permission from Elsevier [43].
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Figure 6. A quantitative meta-analysis of the main risk factors related to mortality. Reprinted from Rubio-Rivas et al., 
with permission from Elsevier [43].
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